State Street SPDR S&P Biotech ETF (XBI) Holdings

Esta página foi traduzida automaticamente do original em inglês por IA; a versão em inglês é a que prevalece. Ler a versão em inglês

Apenas para fins informativos. Não é um conselho financeiro.

Resposta Rápida

State Street SPDR S&P Biotech ETF (XBI) has a last stored price of $149.54, as of the Oct 23, 2026 trading session. It has a 0.35% expense ratio and $7.8B in assets under management.

Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Moderna Inc (MRNA) at 2.25%, and the largest sector allocation is Healthcare at 100.0%.

State Street SPDR S&P Biotech ETF (XBI) ETF — Price, Holdings & Analysis

Visão Geral do ETF

XBI aims to capture the performance of the biotechnology sector within the broader equity market. It tracks the S&P Biotechnology Select Industry Index, utilizing a modified equal-weighting scheme. This approach distinguishes XBI from many other sector ETFs that are capitalization-weighted, meaning XBI gives a larger allocation to smaller companies. By equally weighting its holdings, XBI seeks to reduce concentration risk and provide exposure across the market capitalization spectrum. The fund's top holdings include Moderna Inc (2.25%), Roivant Sciences Ltd Ordinary Shares (1.74%), and Vaxcyte Inc Ordinary Shares (1.73%). XBI is designed for investors seeking targeted exposure to the biotechnology industry, allowing them to take strategic or tactical positions within this specific segment. The fund invests almost exclusively in healthcare companies, with a 100% allocation to the sector. XBI may appeal to investors who believe in the growth potential of the biotechnology industry and seek a diversified approach within that sector.

Métricas de Risco

XBI presents several risks inherent to its investment strategy. As a sector-specific ETF with 100% allocation to healthcare, it lacks diversification across different sectors, making it vulnerable to sector-specific downturns or regulatory changes affecting the biotechnology industry. The fund's beta of 1.47 indicates higher volatility compared to the overall market. While the modified equal-weighted index aims to reduce concentration risk, the top 10 holdings still account for a significant portion of the fund's assets. The expense ratio of 0.35% will create a slight drag on performance over time. Country exposure is heavily concentrated in the United States (94.9%), exposing the fund to primarily US-based economic and regulatory risks.

Beta: 1.47

Taxa de Despesa

0.35%

O que o XBI detém?

Posição	Peso
Moderna Inc (MRNA)	2.25%
Roivant Sciences Ltd Ordinary Shares (ROIV)	1.74%
Vaxcyte Inc Ordinary Shares (PCVX)	1.73%
Arcellx Inc (ACLX)	1.66%
Revolution Medicines Inc Ordinary Shares (RVMD)	1.59%
Praxis Precision Medicines Inc Ordinary Shares (PRAX)	1.57%
Amgen Inc (AMGN)	1.50%
Gilead Sciences Inc (GILD)	1.49%
Amicus Therapeutics Inc (FOLD)	1.48%
Mirum Pharmaceuticals Inc (MIRM)	1.41%

Posições e pesos em 15 de mar. de 2026. Estes dados do fundo têm mais de 45 dias; confirme as posições atuais com o emissor.

Como o fundo está alocado?

Setor	Peso
Saúde	100.0%

País	Peso
Estados Unidos	94.9%
Reino Unido	1.8%
Irlanda	1.4%
Suíça	1.1%
Países Baixos	0.6%
Outros	0.2%

Dividend Yield

0.35%

iShares Morningstar Small-Cap Growth ETF (JKK) — 0.06% expense ratio
ARK Innovation ETF (ARKK) — 0.75% expense ratio
Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio

State Street Income Allocation ETF (INKM) (Multi-Asset) — 0.50% expense ratio
SPDR S&P 600 Small Cap ETF (SLY) (Equity) — 0.15% expense ratio
State Street SPDR S&P Homebuilders ETF (XHB) (Equity) — 0.35% expense ratio

Perguntas e Respostas

What is XBI and what does it track?

XBI, the State Street SPDR S&P Biotech ETF, is an exchange-traded fund that aims to mirror the performance of the S&P Biotechnology Select Industry Index. This index represents the biotechnology sub-industry within the S&P Total Market Index (TMI).

The fund utilizes a modified equal-weighted approach, which differentiates it from capitalization-weighted ETFs.

What is the expense ratio for XBI?

The expense ratio for XBI is 0.35%. This means that for every $10,000 invested in the fund, $35 is used to cover annual operating expenses.

While 0.35% is not the lowest expense ratio available in the equity ETF universe, it is important to consider the specialized exposure XBI offers to the biotechnology sector.

What are the top holdings in XBI?

As of 2026-03-15, the top holdings in XBI are: Moderna Inc (2.25%), Roivant Sciences Ltd Ordinary Shares (1.74%), and Vaxcyte Inc Ordinary Shares (1.73%).

Arcellx Inc (1.66%) and Revolution Medicines Inc Ordinary Shares (1.59%) also rank among the fund's largest positions. These holdings represent a concentrated portion of the fund's overall portfolio, reflecting the specialized nature of the biotechnology sector.

Is XBI a good long-term investment?

Whether XBI is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and outlook on the biotechnology sector. XBI offers targeted exposure to the biotechnology industry, which can be subject to significant volatility.

The fund's beta of 1.47 suggests it is more volatile than the broader market. Past performance does not guarantee future results.

How does XBI compare to similar ETFs?

XBI competes with other biotechnology ETFs, differing primarily in their underlying indexes, weighting methodologies, and expense ratios. XBI's expense ratio is 0.35%.

Some competing ETFs may track different biotechnology indexes or employ market-cap weighting strategies, which could result in different portfolio compositions and performance characteristics. XBI's AUM of $7.79 billion makes it one of the larger biotechnology ETFs available.

Does XBI pay dividends?

Yes, XBI does pay dividends. The current dividend yield for XBI is 0.35%. While this yield is relatively modest compared to some other equity ETFs, it provides a small income component for investors.

The dividend payments are typically distributed quarterly, but this can vary. Investors should note that dividend yields can fluctuate based on market conditions and the dividend policies of the underlying companies held in the ETF.

Aviso Legal: Este conteúdo tem fins informativos apenas e não constitui aconselhamento de investimento. Sempre faça sua própria pesquisa e consulte um consultor financeiro.

Dados fornecidos apenas para fins informativos.

Escrito por uma máquina, sem revisão página a página. A supervisão editorial é sistémica: verificam-se as regras e as fontes, não cada página.